{"schema_version":"secwatch.filing_event.v1","accession":"0001232524-24-000031","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.618680+00:00","generated_at":"2026-06-03T02:14:13.128380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jazz Pharma Q1 GAAP net loss $14.6M, non-GAAP EPS $2.68; affirms FY24 revenue guidance $4.0-4.2B","bullets":["Total revenues $902M (+1% YoY); GAAP net loss $14.6M ($0.23 loss/diluted) vs net income $69.4M ($1.04/diluted) in 1Q23.","Non-GAAP adjusted net income $182.2M ($2.68 EPS) down from $285.3M ($3.95 EPS); cost increases in SG&A and R&D.","Key growth drivers: Xywav +14%, Epidiolex +5%, Rylaze +20% YoY; Xyrem fell 64% to $64.2M.","Oncology revenues +13% to $257.5M; zanidatamab BLA for 2L BTC submitted; Phase 2b suvecaltamide data expected late 1H24.","FY24 guidance affirmed: total revenue $4.0-4.2B, non-GAAP gross margin ~93%, non-GAAP EPS $18.15-19.35."],"urls":{"canonical":"https://secwatch.observer/filing/0001232524-24-000031","json":"https://secwatch.observer/filing/0001232524-24-000031.json","markdown":"https://secwatch.observer/filing/0001232524-24-000031.md","text":"https://secwatch.observer/filing/0001232524-24-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000123252424000031/0001232524-24-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000123252424000031/jazz-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:14:13.128380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1395cdfe1f0fcde602a7c769be94b69f8de2577d","claim":"Jazz Pharmaceuticals plc updated its first quarter of 2024 guidance (reaffirmed).","evidence_excerpt":"Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2024 and affirmed guidance for 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252424000031/0001232524-24-000031-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}